Skip to content
Precision for Medicine
false false
European CRO-Hero European CRO-Hero

Precision European CRO Services

Integrated clinical trial development across Europe, executed with Precision.
With Precision's European CRO services, you gain access to the distinct benefits of expedited patient recruitment, well-equipped sites, dedicated expert investigators, and high-quality outcomes. Our team's extensive experience across the continent adds the essential component of regional expertise to enhance your global clinical strategies.
Europe

Precision European CRO services-Strategic footprint for stronger execution

In 2018, Precision's position as a prominent global CRO with a robust European footprint was strengthened through the acquisition of Argint International, a premier CRO specializing in Central and South-Eastern Europe.

Our strategic presence in Hungary, Poland, Romania, Slovakia, and Serbia facilitates access to a diverse patient pool, expediting patient recruitment. This coupled with a well-established clinical research environment and favorable regulatory ecosystem, delivers a streamlined trial experience.

4. Italy top view from space at night (1)

Rooted in deep regional expertise, with Precision

With Precision’s clinical trial services, data science, and specialty lab services across Europe, we deliver a truly integrated global trial experience.

Our regional team’s expertise is second to none in running successful trials across Europe. This exceptional team of clinical professionals, in-country project managers and regulatory specialists, are well-versed in the regional regulatory, clinical and cultural landscape, and are deeply invested in your clinical program at every stage.

10 Offices across Europe
700 Experts driving clinical excellence
4 Precision labs for integrated clinical development

The Precision team driving your success in Europe

  • Clare Fourrier

    Clare Sarvary Fourrier

    Senior Vice President, Clinical Operations

  • Chris Ingram

    Chris Ingram

    Executive Director, Regulatory Affairs, Europe

  • Katie-McGuire

    Katie McGuire

    Senior Vice President, Regulatory and Site Start-Up

  • Frances Murphy

    Frances Murphy

    Regional Vice President, Clinical Business Solutions, EU & APAC

Agile global delivery models

Precision's worldwide footprint is the cornerstone of our agility and adaptability. Tailored delivery models for your program, striking the perfect balance between onsite and offshore teams for optimized efficiency.

  • Explore

    Full-Service Outsourcing

    Integrated clinical trial management aimed at efficient and accelerated delivery from study start-up through to submission.
    Explore
  • Explore

    Precision FSP

    Augmenting your internal team capacity with Precision experts, based on study, project, and program needs.
    Explore

Global and regional insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies for running successful clinical trials in Europe. 

 

Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat

Discover
Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Clinical Trials

Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat

Discover
Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

Clinical Trials

Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=187570680222, hs_child_table_id=0, hs_updated_at=1742413198455, hs_published_at=1748379090824, description=Christine has been ensuring high performance delivery of clinical research projects for more than 23 years. During this time, she has successfully led diverse teams across various cancer indications including renal, pancreatic, melanoma, lung, head and neck, breast, multiple myeloma, extra-nodal NK/T lymphoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Within the CRO setting she also supported the strategic development of over 50 hematology/oncology programs including complex Phase 1 projects in immuno-oncology and autologous cell therapy. She also led the establishment of a novel oncology research infrastructure which accelerated study activations for Phase 1 solid tumor studies. Christine obtained her master’s degree in public health at the University of Texas where she also trained in the development and implementation of clinical and epidemiologic research at the Coordinating Center for Clinical Trials as well as the Center for Occupational and Environment Health., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christine%20Lusk-1.png',altText='Christine Lusk-1',fileId=187579105870}, lastname=Lusk, hs_initial_published_at=1742410730688, hs_created_by_user_id=26433386, hs_created_at=1742410650472, hs_is_edited=false, hs_deleted_at=0, name=Christine, job=Director, Project Management, slug=christine-lusk, hs_updated_by_user_id=51739740}, second={hs_id=190691157084, hs_child_table_id=0, hs_updated_at=1748379058655, hs_published_at=1748379090824, description=Over the last 15 years, Megan has played a key role in advancing multiple oncology compounds through various stages of development, across numerous tumor types. Having worked at both biotech and CRO companies, Megan brings a comprehensive understanding of clinical operations and drug development. Megan maintains a focus on accelerating the development of innovative cancer therapies to improve patient outcomes worldwide., avatar=Image{width=3024,height=4032,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Megan%20Knoch.jpg',altText='Megan Knoch',fileId=190688034156}, lastname=Knoch, hs_initial_published_at=1748379090824, hs_created_by_user_id=26433386, hs_created_at=1748379018316, hs_is_edited=false, hs_deleted_at=0, name=Megan, slug=megan-knoch, hs_updated_by_user_id=26433386}, third={}})
  • Christine L. avatar

    Christine L.

  • Megan K. avatar

    Megan K.

Discover

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore
Clare Fourrier
Clare Sarvary Fourrier

Senior Vice President, Clinical Operations

Veteran of global oncology clinical operations, with in-depth experience in phase 1-3 oncology and hematology research as well as early-phase studies. Builder of world-class oncology research teams and leader of strategic growth of resources and operations across Europe. Keenly focused on study delivery, mitigation of study risk, and client service.

Chris Ingram
Chris Ingram

Executive Director, Regulatory Affairs, Europe

Chris Ingram, BSc (Hons) is Head of Regulatory Consultancy (Europe) for Precision for Medicine. Chris received his BSc(Hons) in immunology and pharmacology from the University of Strathclyde and has since spent over 21 years working in regulatory affairs with a focus on clinical development. Chris’ regulatory expertise covers clinical development across all phases, regulatory strategy, marketing authorisations, scientific advice, orphan drug designation and paediatric investigation plans across a wide variety of therapeutic areas, including but not limited to, oncology, CNS, metabolic, endocrinology, analgesia and cardiovascular.

Katie-McGuire
Katie McGuire

Senior Vice President, Regulatory and Site Start-Up

Seasoned pharma leader with extensive expertise in oncology drug development and early phase clinical development. Veteran across multiple therapeutic indications in a wide range of multi-country, full-service studies through every phase. Strong communicator and trained executive coach who thrives on change and excels under pressure.

Frances Murphy
Frances Murphy

Regional Vice President, Clinical Business Solutions, EU & APAC

Frances Murphy is a leading authority in clinical CROs, focused on client services and regional growth implementation. Murphy is a dedicated proponent of harnessing truly personalized medicine to develop more effective treatments for patients and brings a high ethical standard to discussions and values transparency and collaboration.